ENLIVEN THERAPEUTICS, INC. Payments of Stock Issuance Costs
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Payments of Stock Issuance Costs of $13.88 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-11-12
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-06-30 was $13.88M.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2024-03-31 was $170.00K, a 96.57% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2023-03-31 was $4.96M.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2021-06-30 was $357.00K.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2023 was $4.96M.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2020 was $1.72M, a 13.93% decline from fiscal 2019.
- ENLIVEN THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2019 was $2.00M.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $13.88M 10-Q · filed 2025-11-12 | ||||
| 2024-03-31 | $170.00K 10-Q · filed 2025-11-12 | ||||
| 2023-12-31 | $4.96M 10-K · filed 2024-03-14 | ||||
| 2023-03-31 | $4.96M 10-Q · filed 2024-11-13 | ||||
| 2023-02-23 | $5.00M 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $2.39M 8-K · filed 2023-06-23 | ||||
| 2021-12-31 | $1.48M 8-K · filed 2023-06-23 | $579.00K 10-K · filed 2022-03-15 | |||
| 2021-06-30 | $357.00K 10-Q · filed 2022-10-25 | $369.00K derived: sum of 2 quarters · filed 2022-10-25 | |||
| 2021-03-31 | $12.00K 10-Q · filed 2021-05-11 | ||||
| 2020-12-31 | $1.72M 10-K · filed 2021-03-05 | ||||
| 2019-12-31 | $2.00M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |